Logotype for Akebia Therapeutics Inc

Akebia Therapeutics (AKBA) investor relations material

Akebia Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Akebia Therapeutics Inc
H.C. Wainwright 27th Annual Global Investment Conference summary8 Sep, 2025

Commercial performance and product focus

  • Vafseo generated over $13 million in Q2 revenue with 55% demand growth, driven by both breadth and depth of prescribing, including 725 prescribers and strong penetration in US Renal Care clinics.

  • Auryxia, despite loss of IP exclusivity, achieved 15% year-over-year growth and continues to contribute to revenue, supported by favorable economics and clinical profile.

  • Vafseo's dosing in real-world use aligns with clinical trial data, with 80% of Q2 prescriptions being refills and average doses increasing over time.

Expansion into dialysis organizations and market opportunity

  • Innovative Renal Care and Dialysis Clinic Inc. have operationalized protocols, providing access to 32,000 patients, with DaVita's pilot potentially opening access to 204,000 patients by year-end.

  • The total addressable market includes 550,000 anemic CKD patients on dialysis, with ongoing efforts to engage Fresenius for future access, targeting P&T committee review in 2026.

Clinical development and future growth drivers

  • The VACE trial aims to demonstrate reductions in hospitalization and mortality, supporting Vafseo's case as a standard of care and offering significant economic benefits to dialysis organizations.

  • The Phase 3 VALOR trial for non-dialysis CKD patients is planned to start by year-end, targeting a similarly sized patient population and representing a multi-billion dollar opportunity.

  • Broad usage of Vafseo has been observed, not limited to home or high-dose ESA patients, indicating strong market acceptance.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Akebia Therapeutics earnings date

Logotype for Akebia Therapeutics Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Akebia Therapeutics earnings date

Logotype for Akebia Therapeutics Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate include Vadadustat, an oral therapy for the treatment of anemia due to chronic kidney disease in non-dialysis and dialysis patients; and AKB-9778, which is intended for the treatment of hypoxia-inducible factor stabilization. Its clinical programs also comprise AKB-6548, for the treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; AKB-5169 for the treatment of pain associated with osteoarthritis; and AKB-6899 for use as a bioavailable prodrug of oxaloacetate to treat disorders accompanied by oxidative stress.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage